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Abstract
Introduction
By improving lipid standardization, the Centers for Disease 
Control and Prevention’s (CDC’s) Lipid Standardization 
Program and Cholesterol Reference Method Laboratory 
Network have contributed to the marked reduction in 
heart disease deaths since 1980. The objective of this study 
was to estimate the benefits (ie, the value of reductions in 
heart disease deaths) and costs attributable to these lipid 
standardization programs.
Methods
We developed a logic model that shows how the inputs 
and activities of the lipid standardization programs pro-
duce short- and medium-term outcomes that in turn 
lead to improvements in rates of cardiovascular disease 
and death. To calculate improvements in long-term out-
comes, we applied previous estimates of the change in 
heart disease deaths between 1980 and 2000 that was 
attributable to statin treatment and to the reduction in 
total cholesterol during the period. Experts estimated the 
share of cholesterol reduction that could be attributed to 
lipid standardization. We applied alternative assumptions 
about the value of a life-year saved to estimate the value 
of life-years saved attributable to the programs.
Results
Assuming that 5% of the cholesterol-related benefits were 
attributable to the programs and a $113,000 value per life-
year, the annual benefit attributable to the programs was 
$7.6 billion. With more conservative assumptions (0.5% of 
cholesterol-related benefits attributable to the programs 
and a $50,000 value per life-year), the benefit attributable 
to the programs was $338 million. In 2007, the CDC lipid 
standardization programs cost $1.7 million.
Conclusion
Our estimates suggest that the benefits of CDC’s lipid 
standardization programs greatly exceed their costs.
Introduction
Cholesterol awareness and control are important fac-
tors in reducing deaths from heart disease in the United 
States and are a key focus of health promotion and clinical 
practice (1). Age-adjusted death rates for heart disease 
have dropped in the United States from 1980 (412.1 per 
100,000 population) to 2000 (257.6 per 100,000 population) 
and 2006 (200.2 per 100,000 population) (2,3). Using a 
model of the impact of various risk factors and treatments 
on heart disease deaths, Ford et al (4) and Capewell et al 
(5) attributed nearly one-third of the reduction in heart 
disease deaths between 1980 and 2000 to a reduction in 
the prevalence of high cholesterol and improved second-
ary prevention using statin drugs to control cholesterol in 
people with previous heart disease.
An important but sometimes overlooked contribution to 
improvements in cholesterol awareness and control has 
been provided by the Centers for Disease Control and 
Prevention’s (CDC’s) Lipid Standardization Program (LSP) 
and Cholesterol Reference Method Laboratory Network 
(CRMLN) (“lipid standardization programs” hereafter). 
The LSP is an accuracy-based program that defines 
benchmark reference methods and maintains stable pools 
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of reference testing materials (6,7). Its standardization 
activities have supported epidemiologic studies that iden-
tified the role of cholesterol in heart disease and clinical 
research laboratories that conducted standardized clinical 
trials to test the effects of alternative treatments to reduce 
cholesterol. The CRMLN is a network of laboratories rep-
licating the CDC reference methods to help manufactur-
ers improve the accuracy of clinical testing methods (8). 
Because only a few manufacturers produce the diagnostic 
equipment and supplies used in cholesterol testing, facili-
tating accurate manufacturer calibration results in more 
accurate clinical testing nationwide (9).
As a cost-saving measure, in 2008 the National Heart, 
Lung, and Blood Institute (NHLBI) retracted its 50-
year budgetary commitment to the LSP. Without the 
NHLBI funding, the LSP and CRMLN programs may 
not be able to continue in their present form. In response, 
the Cardiovascular Biomarker Standardization Steering 
Committee of the National Association of Chronic Disease 
Directors (NACDD) asked NACDD to conduct a cost-ben-
efit study of the LSP. The objective of this study was to 
estimate the benefits and costs of the LSP and CRMLN. 
Results of the study may be used by policy makers to 
determine the value of lipid standardization.
Methods
Logic model development
We first developed a logic model for assessing the impact 
of the CDC lipid standardization programs (Figure 1). 
Logic models are a program evaluation tool used to graphi-
cally depict major elements and causality pathways of 
a program (10). The left side of the logic model lists the 
resources (inputs) necessary for program operation. The 
logic model then shows the major program activities; the 
participants involved with and affected by these activities; 
and the short-, medium-, and long-term outcomes of the 
programs.
The programs are currently supported by CDC and previ-
ously were jointly funded by NHLBI. We do not consider 
participation costs incurred by clinical laboratories, manu-
facturers, and research funding agents because participa-
tion in the programs is voluntary.
The fundamental activities of the programs are to define 
reference methods and maintain reference materials for 
total cholesterol, high-density lipoprotein cholesterol, low-
density lipoprotein (LDL) cholesterol, and triglycerides. 
CDC uses a standardized testing protocol on well-charac-
terized and uniform serum materials to eliminate poten-
tial reference bias and allow program participant results 
to be compared directly to the CDC reference results. The 
programs maintain a set of frozen serum pools that exhibit 
a wide range of lipid concentrations. Long-term mainte-
nance of these pools is essential to ensure that reference 
values of these samples do not drift over time.
Using the reference measurement procedures and mate-
rials, the LSP conducts standardization of clinical labo-
ratories involved in epidemiologic and clinical research. 
Establishing a long-term, accuracy-based reference allows 
results to be compared across different laboratories and 
over time, which is necessary when conducting multi-
center clinical trials; comparing lipid measurement values 
to past values, such as the baseline period in clinical and 
epidemiologic research; or comparing lipid measurement 
values across clinical and epidemiologic research studies. 
Recommended accuracy goals for lipids and lipoprotein 
tests, which include both bias and imprecision, have been 
developed by the National Cholesterol Education Program 
(11-13). These accuracy goals are based on results obtained 
from the LSP.
The CRMLN uses the standardized reference methods and 
materials to certify a network of reference laboratories 
that seek to replicate the accuracy of the CDC laboratory. 
In turn, this network of laboratories certifies participat-
Figure 1. Lipid Standardization Program (LSP) and Cholesterol Reference 
Method Laboratory Network (CRMLN) logic model. Abbreviations: CDC, 
Centers for Disease Control and Prevention; NHLBI, National Heart, Lung, 
and Blood Institute; PI, principal investigator; QALY, quality-adjusted life-year. 
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ing manufacturers and clinical testing laboratories. By 
calibrating manufacturers’ equipment and testing meth-
ods against the CDC reference standards, the CRMLN 
increases the accuracy of all tests conducted using these 
supplies, even for clinical laboratories that do not partici-
pate in the program. This system allows for accurate com-
parison of test results to the clinical practice guidelines 
established by the Adult Treatment Panel III (14).
The programs’ inputs, activities, and participants are 
intended to produce the following short-term outcomes:
• Standardized epidemiologic results, which lead to 
improved treatment recommendations.
• Standardized clinical trials, which lead to improved 
comparisons of alternative treatments.
• Standardized routine testing methods, which lead to 
the improved cholesterol test accuracy necessary for 
improved diagnosis.
The short-term outcomes — in combination with non-
program factors — lead to the following medium-term 
outcomes for patients and health care providers: increased 
cholesterol awareness, better practice patterns, improved 
diet and exercise, better drugs, and improved diagnosis of 
patients with high cholesterol.
The medium-term outcomes combine to produce better 
cholesterol control, which improves patient health out-
comes in the long term by reducing medical events and 
lowering rates of cardiovascular disease and death. The 
true benefits of the lipid standardization programs arise 
from improvements in these long-term patient outcomes.
Quantifying outcomes
It is difficult to quantify precisely the effect of the lipid 
standardization programs on these short-, medium-, and 
long-term outcomes. For most of the outcomes, stan-
dardization of lipid measures is a prerequisite that can 
support and promote — but does not by itself guarantee 
— improved public health outcomes. For example, stan-
dardization supports clinical trials of new cholesterol-low-
ering therapies, but development of new therapies also 
depends on research and development efforts, technologic 
breakthroughs, and careful clinical testing.
Because we cannot directly attribute outcome changes 
to program operations, our approach is to investigate 
improvements in each short- and medium-term outcome 
during recent years. We discuss qualitatively how the 
standardization efforts of CDC programs may have facili-
tated the improvement, but we do not attempt to estimate 
precisely the share of each improvement that is attribut-
able to the programs. We also do not place a dollar value 
on the benefits of improvements in short- and medium-
term outcomes because the true benefits to patients are 
associated with improvements in long-term outcomes.
To determine the improvements in long-term outcomes, 
we applied previous estimates of the change in heart dis-
ease deaths between 1980 and 2000 that was attributable 
to treatment with statins and the overall reduction in total 
cholesterol during the period. Ford et al (4) and Capewell 
et al (5) estimated that these cholesterol-related changes 
prevented or postponed more than 111,000 deaths and 
saved 1.35 million life-years in 2000 (Table 1).
We considered alternative assumptions about the share of 
deaths prevented or postponed and life-years saved that 
were attributable to the lipid standardization programs. 
We asked experts to estimate the percentage of lipid 
reduction during the period that was attributable to the 
lipid standardization programs. The 4 experts work on 
cardiovascular disease in various settings (1 in a univer-
sity hospital, 2 in private clinical laboratories, and 1 in the 
National Institutes of Health). The experts were asked to 
base their estimates on information on the reduction in 
CHD deaths between 1980 and 2000 and the estimate (4) 
that 24% of the reduction was due to lower cholesterol lev-
els. They were told that lipid standardization was poten-
tially one of many factors contributing to lower lipid levels. 
The experts’ median estimate of the share of lipid reduc-
tion attributable to lipid standardization was 5%, but the 
estimates ranged widely (from 2%-3% to >50%). We also 
considered more conservative estimates of 0.5% and 1%.
To estimate the dollar value of improvements in life expec-
tancy, we applied alternative estimates of the value of a 
life-year gained. Setting a dollar value on life-years gained 
is controversial. In the health economics literature, a value 
of $50,000 per quality-adjusted life-year (QALY) is some-
times used to assess the cost-effectiveness of interventions, 
but the conceptual basis for this benchmark is debatable 
(15). A recent study suggests that society’s willingness 
to pay for health improvements is at least $113,000 per 
QALY in the United States (16). For regulatory purposes 
in cost-benefit analyses of environmental issues, the 
Environmental Protection Agency (EPA) sets the value 
of a statistical life-year at $300,000. The EPA estimate is 
based on an estimate of $4.8 million in 1990 dollars (17) 
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for 1 statistical life that was calculated using wage differ-
entials for risky jobs in the labor market. To convert this 
value into a value for a statistical life-year, we multiplied 
$4.8 million by 1.49, the gross domestic product inflator 
for 2008 relative to 1990. We assumed that the resulting 
value of a statistical life-year in 2008 represented the net 
present value of a stream of constant statistical life-year 
payments received over 40 years (the approximate remain-
ing life expectancy of a 45-year-old adult) with a real 
discount rate of 3%. Solving for the value of a statistical 
life-year yields a value of $300,000 per life-year.
We calculated the dollar benefits of the life-years gained 
attributable to the lipid standardization programs under 
alternative assumptions about the life-years attribut-
able to the LSP and CRMLN and the value of a life-year 
gained. We then compared the dollar benefits of the pro-
grams to the cost of the LSP and CRMLN in fiscal year 
2008, $1.7 million.
Results
As detailed in the Appendix, we found suggestive evidence 
linking the LSP and CRMLN to improved short- and medi-
um-term outcomes. Program data indicate that laborato-
ries participating in the programs achieve high levels of 
accuracy. This accuracy supports standardized epidemio-
logic results, standardized clinical trials, and standardized 
testing methods used by clinical laboratories, which can 
lead to improved test accuracy.
Assuming the median expert panel estimate of 5% of the 
cholesterol-related benefits attributable to the programs 
and a value per life-year of $113,000, the benefits attribut-
able to the programs are estimated to be $7.6 billion (Table 
2). Assuming the most conservative estimates (0.5% of the 
cholesterol-related benefits attributable to the programs 
and a $50,000 value per life-year), the benefits attributable 
to the programs are estimated to be $338 million annually.
We conducted a sensitivity analysis to examine how the 
estimated benefits change under alternative assumptions 
about the percentage attributable to the LSP and CRMLN 
(Figure 2) in comparison to this cost. Both the percent-
age attributable and the benefits and costs are presented 
using logarithmic scales to preserve the true linear rela-
tionship between the benefit and the percentage attribut-
able and to allow the benefits and costs to be shown in 
the same figure (otherwise, the benefit at 5% attributable 
would completely dwarf the cost of the programs). Even 
assuming that the LSP and CRMLN are responsible for 
only 0.01% of the improvement in life-years attributable 
to cholesterol-related factors, the benefits of the programs 
substantially exceed their costs.
Discussion
Our estimates suggest that the benefits of CDC’s lipid stan-
dardization programs greatly exceed their costs. Deaths 
from heart disease fell dramatically between 1980 and 
2000 (2,3), and this reduction has driven improvements 
in overall life expectancy. The improvement in life-years 
has high dollar value. A significant share of the improve-
ment in heart disease deaths is due to cholesterol-related 
factors, including the overall reduction in total and LDL 
cholesterol and the use of statin drugs for secondary and 
primary prevention (4,5). To the extent that some of the 
improvement in these cholesterol-related factors is due to 
CDC’s lipid standardization programs, the programs have 
large dollar benefits because the overall dollar value of the 
increase in life-years from heart disease — and the share 
of the increase that is attributable to cholesterol-related 
factors — is so large. Put another way, the overall benefits 
of cholesterol reduction are so large that there is plenty of 
credit to go around to lipid standardization programs and 
other factors (eg, research and development efforts, tech-
nological breakthroughs, careful clinical testing) affecting 
cholesterol. Even if the LSP and CRMLN receive only a 
small share of the credit, the programs’ benefits exceed 
their costs.
Figure 2. Benefits of life-years gained from the Lipid Standardization 
Program (LSP) and Cholesterol Reference Method Laboratory Network 
(CRMLN). Cost of the programs was $1.7 million per year. 
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Our analysis has several potential limitations. First, our 
estimates could implicitly overestimate the value of the 
improvements in life expectancy stemming from reduc-
tions in heart disease deaths; however, this does not 
appear to be the case. Improvements in heart disease 
deaths are clearly documented in national life expec-
tancy and cause-of-death data. Less evidence exists on the 
value of this improvement, but a study by Murphy and 
Topel (18) provides context for our estimates. They esti-
mated that the reduction in deaths from heart disease has 
increased the value of life by about $1.5 trillion per year 
since 1970. The Capewell et al study (5) — which is the 
basis for our estimates — found that 3.15 million life-years 
were gained in 2000 from all reductions in heart disease 
deaths between 1980 and 2000. When this gain is valued 
at $50,000, $113,000, and $300,000 per life-year, the total 
benefits in 2000 would be $155 billion, $350 billion, and 
$930 billion, respectively. Thus, the overall benefit from 
reduction in heart disease deaths given by Murphy and 
Topel is even greater than the underlying heart disease 
benefit in our analysis.
Second, our analysis could attribute too much of the gain 
in life-years resulting from reductions in heart disease 
deaths to cholesterol-related factors. We relied on studies 
by Ford et al (4) and Capewell et al (5), which appear to 
provide the most comprehensive decomposition of the gain 
in life-years that are attributable to specific factors.
Third, our estimate depends on the share of lipid reduction 
that is attributable to the lipid standardization programs, 
and this parameter was not precisely measured. Although 
the parameter was based on the opinion of experts familiar 
with the programs, these experts noted that the parameter 
was difficult to estimate. Even when we included more 
conservative parameters, the benefits attributable to the 
programs were still sizeable. Because this is probably 
the most important potential limitation of our study, it is 
worth considering additional alternative estimates. The 
sensitivity analysis shows how the benefits change with 
the percentage attributable to the LSP and CRMLN for 
values ranging from 0.001% to 5%. Even when the LSP 
and CRMLN are responsible for a smaller share of the 
reduction in life-years attributable to cholesterol-related 
factors than our expert panel estimated, the benefits of the 
programs substantially exceed their costs.
Fourth, our estimate of the benefits attributable to the pro-
grams is based on the estimated effects of the programs on 
cholesterol between 1980 and 2000. It is not clear whether 
standardization would suffer today and in the future if the 
LSP and CRMLN ceased to exist. One might expect that 
test values would drift away from true values over time, 
but it seems unlikely that bias levels would return to their 
1980 levels. This limitation can be assessed using Figure 
2. Suppose that 1% of the improvement in cholesterol-
related factors is due to LSP and CRMLN effects between 
1980 and 2000. If 10% of this improvement would be lost 
if the programs ceased to exist, then the lost benefit would 
equal 0.1% of the overall cholesterol-related effects. The 
programs’ benefits would still substantially exceed their 
costs.
Fifth, our estimates of the improvements in heart disease 
deaths that are attributable to cholesterol-related factors 
are based on studies for the period between 1980 and 
2000. If more recent data were available, the number of 
life-years saved by cholesterol-related factors would likely 
increase because heart disease death rates have continued 
to fall since 2000.
Sixth, assigning a dollar value to life-years saved is con-
troversial, and when a value is assigned, debate remains 
about the actual value to set. Nevertheless, the estimated 
benefit from the lipid standardization programs remains 
high even if life-years are valued at $50,000 per year.
Finally, our analysis does not include health care cost 
offsets or increases associated with the reduction in heart 
disease deaths. In principle, it might be possible to model 
spending on heart disease for individual patients; how-
ever, the level of modeling necessary is beyond the scope 
of this study.
This is the first study attempting to quantify the benefits 
of CDC’s lipid standardization programs. At least 1 study 
has assessed the benefits of improving the accuracy of 
other clinical tests. Gallaher et al (19) estimated that sys-
tematic errors on calcium tests could increase the costs of 
follow-up testing and procedures by $60 million to $199 
million per year. Although that study applied different 
methods and examined a different test than our study, it 
provides support for our general finding that improving 
test accuracy may have substantial financial benefits.
As noted in the introduction, the NHLBI discontinued 
its funding of the LSP in 2008, raising questions about 
the program’s future. Our estimates provide evidence of 
the benefits and costs of the CDC lipid standardization 
programs that may help policy makers decide whether to 
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continue funding the programs.
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Tables
Table 1. Deaths Prevented or Postponed and Life-Years Gained 
Attributable to Cholesterol-Related Factors, 2000a 
Factor
Deaths Prevented or 
Postponed
Life-Years 
Gained
Statin treatment 28,785 29,125
Reduction in the prevalence of 
high cholesterol
82,800 1,102,100
Total 111,585 1,351,225
 
a Source: Capewell et al (5). Data from Ford et al () were used to calculate 
the deaths prevented or postponed and life-years gained that were attribut-
able to treatment with statins.
Table 2. Benefits of Life-Years Gained From the Lipid 
Standardization Program (LSP) and Cholesterol Reference 
Method Laboratory Network (CRMLN)a
Estimates Benefits, $ (Millions)
% Attributable 
to the LSP and 
CRMLN
Life-Years 
Gained
$50,000 
per Life-
Year
$113,000 
per Life-
Year
$300,000 
per Life-
Year
0.5 6,756 338 763 2,027
1 13,512 676 1,527 ,05
5 67,561 3,378 7,63 20,268
 
a Benefits calculated as the share of cholesterol-related benefits attributable 
to the programs multiplied by the share of life-years gained that is attribut-
able to cholesterol-related factors multiplied by the value of a life-year.
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The following is an excerpt from: Hoerger TJ, Wittenborn JS, Couper S. 
Lipid standardization program: cost-benefit analysis: final report. Research 
Triangle Park (NC): RTI International; 2010.
3.1 Short-Term Outcomes: Improvements in Laboratory 
Standardization for Cholesterol Testing
The immediate outcome of improved lab standardization and manufacturer 
certification is an increase in the accuracy of cholesterol testing. The inten-
tion of the CDC lipid standardization programs is to improve the accuracy 
and comparability of research-related testing, primarily through the Lipid 
Standardization Program (LSP), and to improve the accuracy of general 
clinical tests directly through the Cholesterol Reference Method Laboratory 
Network (CRMLN). There is strong evidence that laboratory performance on 
cholesterol testing has improved through standardization during the past 25 
years, although it is difficult to say how much of the improvement has been 
due to the LSP and CRMLN.
3.1.1 Accuracy of LSP Standardized Laboratories
The goal of the LSP is to ensure that member labs exhibit consistent accu-
racy in lipid testing over time. Early lipid testing was subject to significant 
levels of error and bias, so initial efforts of the LSP focused on improving 
the accuracy of lipid testing through the development and establishment of 
reference testing methods. As standardization was achieved, the LSP focus 
turned to maintaining accuracy of lipid testing. Table 3-1 shows the percent-
age bias and coefficient of variation (CV) of LSP standardized labs (based on 
part III standardization maintenance surveys among newly enrolled labs that 
entered the program in each year) since electronic recordkeeping began in 
1999. The results show that average bias levels have remained below 2% 
from 1999 through 2007 and have decreased by 0.7% percentage points 
over that time period. Labs are considered standardized if neither their 
percentage bias nor their CV exceeds 3%. Over that same period, less than 
10% of surveys exhibited a bias of more than 3% except in 1999 and 2001, 
and no surveys yielded a CV of more than 3%. Note that the low number of 
observations may preclude drawing significant conclusions on the trend of 
“failing” labs over time.
3.1.2 Accuracy of Labs in CRMLN Clinical Laboratory 
Certification Program
Although the LSP results demonstrate that standardization is being achieved 
among the limited number of research-oriented LSP standardized labs, 
the primary mechanism through which the CDC laboratory standardization 
programs may increase clinical testing accuracy is through the CRMLN. The 
CRMLN labs are intended to replicate CDC reference methods to extend 
the reach of standardization, most importantly through the manufacturer 
certification process. The manufacturer certification process allows manu-
facturers to calibrate their equipment and supplies against accuracy-based 
reference values. When used by clinical testing labs, the calibrated supplies 
will presumably increase the accuracy of clinical testing conducted by these 
labs. A resource for evaluating how well this program works is to look at data 
from clinical laboratories that participate in the CRMLN’s Clinical Laboratory 
Certification Program. Table 3-2 shows the average percentage bias and 
average percentage CV among clinical laboratories participating in this pro-
gram since 2000. Panel 3.2.a shows results for all labs applying to obtain or 
maintain certification, and Panel 3.2.b shows results for the subset of labs 
that obtained certification. As with the LSP standardized labs, the results 
show consistently low and improving bias and CV values.
3.1.3 CAP Survey Results Show Improvement in 
Clinical Labs
Although the above tables show that standardization is being achieved 
among labs participating in the LSP and CRMLN, these results do not directly 
reflect the accuracy of the many nonprogram labs that conduct patient clini-
cal testing. Table 3-3 shows the results of CAP proficiency testing surveys 
for total cholesterol for major methods/instruments peer groups between 
Table 3-1. Accuracy of LSP-Standardized Labs, 1999–2007
Year Observations % Absolute Bias % CV
% with Bias > 3% in 
Absolute Value % with CV > 3%
1999 16 1.88 1.61 13% 0.00%
2000  1.2 1.5 0% 0.00%
2001 16 1.55 0.96 19% 0.00%
2002 36 1.2 1.07 6% 0.00%
2003 60 1.07 1.37 0% 0.00%
200 8 1.2 1.3 0% 0.00%
2005 0 1.28 1.19 8% 0.00%
2006 2 1.2 1.21 % 0.00%
2007 2 1.16 1.38 % 0.00%
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2000 and 2006. This period was selected because the CAP specimens were 
relatively free of matrix effects and CDC performed confirmatory testing on 
the materials used in the program. With the exception of 2001, we used the 
specimen in the year’s A survey whose total cholesterol confirmatory value 
was closest to 200 mg/dL. Because the 2001 A survey was not available to 
us, we used the specimen in the B survey with a confirmatory value closest 
to 200 mg/dL.
Table 3-3 shows that bias and CV have remained consistently low and 
continue to show improvement at the method/instrument level, with the 
average absolute value of bias falling from 1.2% in 2000 to 0.7% in 2006, 
and the CV remaining unchanged. Four out of 3 methods/instruments had 
biases > 3% in absolute value in 2000 compared with 1 out of 21 in 2006; 
the corresponding figures for CV were 6 out of 3 in 2000 compared with 2 
out of 21 in 2006.
Improvements in standardization have likely been much larger over a longer 
period, although the available data are not ideal for making long-term com-
parisons. Table 3- shows laboratory performance on CAP surveys in 1985 
and 2009. These results show clear improvement in the bias (as measured 
by the percentage difference between a method/instrument mean and the 
all method/all instrument mean) and CV for each method/instrument. In 
1985, about half of the method/instrument groups had biases greater than 
3% in absolute value, and all but two method/instrument groups had CVs 
greater than 3%. In 2009, only one method/instrument group had a bias 
greater than 3% in absolute value, and only one group had a CV greater than 
3%. However, the specimens used in 1985 and 2009 did not closely resem-
ble patient samples and may have been subject to matrix effects (mean-
ing that an instrument could perform well on patient samples but produce 
biased results on alterated, nonpatient samples). Nevertheless, the dramatic 
improvements shown in bias and in particular CV (which may be less suscep-
Table 3-2. Accuracy of Clinical Laboratories Participating in CRMLN Certification, 2000–2009
3.2.a All Labs Applying to Obtain or Maintain Certification
Year Observations
Average % Bias 
(Absolute Value) Average % CV
% with Bias > 3% in 
Absolute Value % with CV > 3%
2000 67 1.77 1.269 18% 3%
2001 31 1.61 1.197 15% 2%
2002 86 1.590 1.11 11% 1%
2003 35 1.11 1.083 11% 1%
200 50 1.599 1.12 11% 1%
2005 3 1.509 1.22 12% %
2006 63 1.8 1.072 10% 2%
2007 1 1.512 1.129 10% 1%
2008 17 1.511 1.172 13% 1%
2009 08 1.98 1.151 12% 1%
3.2.b Subset of Labs that Passed Certification
Year 0bservations
Average % Bias 
(Absolute Value) Average % CV
% with Bias > 3% in 
Absolute Value % with CV > 3%
2000 36 1.197 1.18 0.5% 1.1%
2001 356 1.196 1.117 0.6% 0.8%
2002 22 1.257 1.029 0.9% 0.0%
2003 371 1.09 1.005 0.3% 0.0%
200 382 1.101 1.050 0.0% 0.3%
2005 367 1.17 1.091 0.3% 0.5%
2006 06 1.199 0.999 0.0% 0.2%
2007 390 1.232 1.090 0.8% 0.3%
2008 350 1.130 1.117 1.1% 0.3%
2009 351 1.080 1.095 0.3% 0.6%
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tible to matrix effects) clearly suggest that standardization of labs occurred 
over this period.
CAP launched its Accuracy Based Lipid (ABL) Survey in 2008 to eliminate or 
minimize matrix effects and provide better measures of the accuracy and 
harmonization of cholesterol testing. Results from the 2009 ABL (Table 3-5) 
suggest that almost all participating laboratories meet current NCEP stan-
dards for total cholesterol (total error within 9% of the target level). Most par-
ticipating laboratories meet National Cholesterol Education Program (NCEP) 
standards for HDL cholesterol (total error within 13% of the target level), 
although the performance is not as strong as on total cholesterol. The ABL 
should be useful for identifying trends in laboratory accuracy as more years 
of data become available.
3.2 Medium-Term Outcomes
Increasing the accuracy of research and clinical testing will result in several 
medium-term outcomes, including improving clinical diagnosis rates and 
Table 3-3. CDC Confirmed CAP Survey Results, 2000–2006
Year
Number of 
Labs
Number of 
Methods/ 
instruments Mean SD
Weighted 
Average Bias 
(% Absolute 
Value) CV%
Number of 
Methods with 
bias >3% 
in Absolute 
Value
Number of 
Methods with 
CV > 3%
2000 ,731 3 208.1 5.2 1.18 2.5 /3 6/3
2001 ,56 27 19.1 5.0 1.3 2.6 2/27 /27
2002 ,330 26 188.8 .6 0.87 2.5 2/26 6/26
2003 ,90 25 197.2 5.0 1.89 2.5 7/25 7/25
200 ,156 23 196.8 .8 1.35 2. 3/23 /23
2005 3,962 23 202. 5.0 0.98 2.5 0/23 /23
2006 ,080 21 201.8 .8 0.69 2. 1/21 2/21
Table 3-4. Laboratory Performance on CAP Proficiency Testing, 1985 and 2009
Year
Number of 
Labs
Number of 
Methods/ 
Instruments Mean SD
Weighted 
Average Bias 
(% Absolute 
Value)
Weighted 
average CV%
Number of 
Methods with 
Bias >3% in 
Absolute Value
Number of 
Methods with 
CV > 3%
1985 ,716 30 257.2 12.5 .5 5.2 15/30 28/30
2009 ,770 20 203.0 . 1.67 2.2 1/20 1/20
Source: 1985—Laboratory Standardization Panel of the National Cholesterol Education Program, 1988; 2009—College of American Pathologists, 2009a. The 
underlying data are shown in Appendix Tables A-1 and A-2.
Table 3-5. Percentage of Laboratories Meeting NCEP Targets
 
Total Cholesterol (within 10% of target)
ABL-01 ABL-02 ABL-03
Target 152.6 mg/dl 180.0 mg/dl 2.2 mg/dl
Labs 98.6% 100% 99.3%
 
HDL Cholesterol (within 13% of target)
ABL-01 ABL-02 ABL-03
Target 33.9 mg/dl 56.8 mg/dl 9.3 mg/dl
Labs 77.% 96.6% 91.8%
Source: College of American Pathologists, 2009b.
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improving cholesterol-related research. Standardization of research testing 
has facilitated several important events, from the early research linking ele-
vated total and LDL cholesterol to higher mortality, to more focused, clinical 
research on the efficacy of treatment and prevention interventions, including 
drugs and diet and exercise changes. Together, these findings have allowed 
for the creation of the ATP practice guidelines and provided the impetus for 
numerous public health campaigns targeted toward increasing physician 
and public awareness of the risks of high cholesterol and its modifiable risk 
factors.
3.2.1 Improved Clinical Diagnosis Rates
Better laboratory accuracy facilitates better diagnosis of persons with high 
cholesterol. If a laboratory produces biased cholesterol readings, some 
patients who truly need cholesterol reduction may not receive treatment, 
whereas other patients who do not need treatment may receive it. We used 
the data on bias from the method/instrument observations underlying Table 
3-3 to estimate the percentage of patients whose total cholesterol would 
be misclassified in 2000 and 2006. We examined the ATP III cutoffs of 200 
Table 3-6. Percentage of Patients Misclassified in 2000 and 2006, Based on Total Cholesterol, Men
 
True Desirable 
<200 mg/dl
True Borderline 
200–239 mg/dL
True High 
>240 mg/dl
Reported as 
Desirable
Reported as 
Borderline
Reported as 
Desirable
Reported as 
Borderline
Reported as 
High
Reported as 
Borderline Reported as High
True values 8.0% — — 3.6% — — 17.%
2000 6.% 1.6% 0.7% 32.7% 1.1% 0.5% 16.9%
2006 6.9% 1.1% 0.3% 33.5% 0.7% 0.2% 17.2%
Table 3-7. Percentage of Patients Misclassified in 2000 and 2006, Based on Total Cholesterol, Women
 
True Desirable 
<200 mg/DL
True Borderline 
200 – 239 mg/dL
True High 
>240 mg/dl
Reported as 
Desirable
Reported as 
Borderline
Reported as 
Desirable
Reported as 
Borderline
Reported as 
High
Reported as 
Borderline Reported as High
True values .5% — — 33.8% — — 21.7%
2000 3.0% 1.5% 0.7% 31.9% 1.2% 0.5% 21.2%
2006 3.5% 1.0% 0.3% 32.7% 0.8% 0.2% 21.5%
Table 3-8. Percentage of Patients Misclassified in 1985 and 2009, Based on Total Cholesterol, Men
 
True Desirable 
<200 mg/dl
True Borderline 
200–239 mg/dL
True High 
>240 mg/dl
Reported as 
Desirable
Reported as 
Borderline
Reported as 
Desirable
Reported as 
Borderline
Reported as 
High
Reported as 
Borderline Reported as High
True values 8.0% — — 3.6% — — 17.%
1985 3.% .6% 3.5% 27.5% 3.6% 2.1% 15.3%
2009 6.% 1.6% 1.7% 31.8% 1.1% 1.0% 16.%
Table 3-9. Percentage of Patients Misclassified in 1985 and 2009, Based on Total Cholesterol, Women
 
True Desirable 
<200 mg/DL
True Borderline 
200 – 239 mg/dL
True High 
>240 mg/dl
Reported as 
Desirable
Reported as 
Borderline
Reported as 
Desirable
Reported as 
Borderline
Reported as 
High
Reported as 
Borderline Reported as High
True values .5% — — 33.8% — — 21.7%
1985 0.2% .3% 3.3% 26.8% 3.7% 2.3% 19.%
2009 3.0% 1.5% 1.6% 31.0% 1.2% 1.1% 20.6%
VOLUME 8: NO. 6
NOVEMBER 2011
12 Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2011/nov/10_0253.htm
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position  
of the Centers for Disease Control and Prevention.
and 20 mg/dl to distinguish between desirable, borderline, and high total 
cholesterol. We used cholesterol information for U.S. adults from the 1988–
199 National Health and Nutrition Examination Survey (NHANES III), as 
reported in the ATP III report (ATP III, 2002), to calculate separate total cho-
lesterol population distributions for men and women. For men, the data are 
roughly consistent with a normal distribution with mean 202 and variance 
0.5. For women, the data are roughly consistent with a normal distribution 
with mean 206 and variance 3.5. Using the percentage bias for each indi-
vidual laboratory method in 2000 and 2006 from the data underlying Table 
3-3, we calculated the percentage of people misclassified relative to the 
“true” ATP-III distributions. For example, if the true distribution for males was 
distributed normally with a mean of 200 and variance of 10, then we would 
expect to find 50% of men classified as having desirable cholesterol (<200 
mg/dl); however, if an individual laboratory method had 5% bias so that its 
distribution of cholesterol values was distributed normally with a mean of 
210 and variance of 10, then too few men would be classified as having 
desirable cholesterol level and too many would be put into the borderline or 
high cholesterol categories.
Tables 3-6 and 3-7 show the percentage of adults whose total cholesterol 
would be correctly reported (so that a patient’s reported value is the same 
as the true value, as highlighted in green) and the percentage that would 
be misclassified (so that the patient’s reported value is not the same as the 
true value, as highlighted in red) in 2000 and 2006. The reduced bias in 
2006 leads to fewer misclassifications. In 2000, a total of 3.9% of the male 
population would have been misclassified, including 0.5% of the population 
with true high cholesterol who would have been reported as having border-
line cholesterol. In 2006, misclassifications reduced to 2.3% of the male 
population, including 0.2% of the population with true high cholesterol who 
would have been reported as having borderline cholesterol. Values for the 
female population exhibit the same trend toward fewer misclassifications.
If we conduct this same exercise using the 1985 and 2009 CAP proficiency 
testing survey data, the share of the population that would be misclassified 
is much larger (Tables 3-8 and 3-9) in 1985 with misclassifications fall-
ing dramatically by 2009. These results should be interpreted cautiously, 
however, because these specimens may have included matrix effects that 
distorted the true bias in patient samples.
3.2.2 Practice Patterns
High levels of cholesterol, including LDL cholesterol, were not definitively 
linked to increased risk of heart disease until the publication of the results 
of the Lipid Research Clinics Coronary Primary Prevention Trial in 198 
(Lipid Research Clinics Program, 198). In 1985, NHLBI formed NCEP to 
organize public health efforts to reduce cholesterol-attributable heart dis-
ease. At the heart of these efforts are the clinical practice guidelines, the 
latest of which is the Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (ATP III, 2002).
To produce the practice guidelines, NCEP and its partners had to synthesize 
data from a number of sources to produce a comprehensive cholesterol 
control strategy. For example, epidemiological and clinical trials have dem-
onstrated the harms of high cholesterol in the overall population and the 
degree of elevated risk among subpopulations. Other trials have assessed 
the efficacy of treatment to reduce high cholesterol. Finally, epidemiological 
surveys such as NHANES are necessary to identify actual cholesterol levels 
in the population. Combining the outcomes of such disparate studies is only 
possible when the cholesterol values of each study are directly comparable. 
To achieve comparability, the major cholesterol studies used to produce 
the practice guidelines have depended on LSP standardized labs to ensure 
accuracy and allow comparability.
3.2.3 Cholesterol Awareness
An important goal of public health programs focused on cholesterol is to 
increase awareness of the risks of high cholesterol among physicians and 
the general public. NCEP has focused efforts in two key areas: (1) improving 
clinical practice to increase the detection of high cholesterol and improve 
cholesterol treatment, and (2) increasing public awareness of the risks of 
high cholesterol to promote cholesterol-reducing lifestyle choices. By work-
ing with physician associations, continuing to refine the ATP guidelines, and 
conducting national conferences on cholesterol, NCEP continues to focus on 
physician education and training. NCEP has also focused on public health 
information campaigns, including the Know Your Number campaign to high-
light the risks of high cholesterol among the general public and the Healthy 
People 2000 and Healthy People 2010 campaigns, which set defined tar-
gets for population cholesterol control.
NCEP efforts to improve physicians’ understanding of the risks of cholesterol 
on CHD appear to have been largely successful. The NHLBI Cholesterol 
Awareness Surveys found that the number of patients who had ever had 
their cholesterol levels checked increased from 35% to 75% between 1993 
and 1995 (NHLBI Cholesterol Awareness Surveys press release, December 
1995). This survey also found that physicians had lowered the threshold 
for initiating cholesterol reduction treatment and were generally in compli-
ance with the ATP guidelines. A CDC study using Behavioral Risk Factor 
Surveillance System data found that the proportion of people who reported 
having their blood cholesterol screened in the preceding 5 years increased 
from 67.6% in 1991 to 73.1% in 2003 (Saddlemire et al., 2005). However, 
recent evidence finds that lower rates of dietary and pharmacologic therapy 
initiation remain among certain physician groups, indicating that education 
efforts need to continue (Yarzebski, Bujor, & Goldberg, 2002).
As with the development of the clinical guidelines, public health information 
campaigns are ultimately the product of multiple and disparate sources of 
data on the risks of high cholesterol and the effectiveness of different treat-
ment and prevention strategies; as with the formation of the practice guide-
lines, this is possible only when the data used are directly comparable due 
to the underlying accuracy of the cholesterol measurements. Thus, the CDC 
lipid standardization programs have played an important role in facilitating 
the research necessary to inform, guide, and bolster public health informa-
tion efforts.
3.2.4 Cholesterol-Lowering Drugs
There have been clear improvements in drug therapies to reduce LDL cho-
lesterol levels and/or increase HDL cholesterol levels in recent years (the 
LSP does not standardize LDL testing, although the CRMLN does; to esti-
mate LDL levels, most U.S. laboratories use the Friedewald equation, which 
depends on total cholesterol, HDL cholesterol, and triglyceride measures 
that are standardized by both programs). In particular, the introduction and 
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widespread adoption of statins has revolutionized cholesterol management. 
Currently, six statins (atorvastatin, fluvastatin, lovastatin, pravastatin, rosu-
vastatin, and simvastatin) are approved for use in the United States. These 
statins have been shown to reduce LDL cholesterol by 3% to 55%, with 
the most recently approved statins producing the largest reductions (Senior 
Journal, 2005). Other cholesterol-lowering drugs include ezetimide, nictonic 
acid, fenofibrate, and gemfibrozil.
The standardization of cholesterol measurement has played an important 
but difficult-to-quantify role in the development of cholesterol-lowering drugs. 
Cholesterol-lowering drugs are approved based primarily on their safety and 
their efficacy in lowering LDL cholesterol levels. To assess efficacy, it is nec-
essary to accurately and reliably measure cholesterol levels. Standardization 
of cholesterol testing allows a large number of patients to be tested in 
large, multicenter clinical trials. Standardization also facilitates compari-
sons across trials and allows improvements in cholesterol to be assessed 
in the context of previous epidemiological studies showing the relationship 
between standardized cholesterol levels and clinical outcomes.
3.2.5 Diet and Exercise
In addition to pharmacological cholesterol reduction treatment, diet and 
exercise are important for ensuring reductions in cholesterol levels. On the 
basis of observational study findings, ATP III lists physical inactivity and an 
atherogenic diet (which generally includes high cholesterol) as major modifi-
able risk factors for high levels of LDL cholesterol and low levels of HDL 
cholesterol. The consumption of saturated fats and cholesterol has been 
falling since the early 1970s. In 1972, the average American consumed 
355mg of cholesterol and 13.2g of saturated fat with a total energy intake 
of 1,983 kilocalories per day. By 1990, the cholesterol and fat intake 
measures had improved to 291mg of cholesterol and 12.6g of saturated 
fat with 2,199 kilocalories consumed per day (Ernst, Sempos, & Briefel, 
1997). So while total caloric intake has markedly increased, cholesterol 
and saturated fat have decreased both in proportional and absolute lev-
els. In the following decade, the proportion of calories from saturated fat 
continued to fall, although total cholesterol intake decreased only in men 
and actually increased by 11g per day in women (Carroll, Lacher, & Sorlie, 
2005). However, the consumption of LDL cholesterol has decreased (Carroll, 
Lacher, & Sorlie, 2005). As with cholesterol medications, the evidence for 
the efficacy of lifestyle interventions to mitigate these risk factors came from 
clinical and epidemiological research, which, in most cases, benefited from 
increased accuracy due to the LSP.
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